Hydromorphon Kalceks (Hydromorphone Hydrochloride)

Hydromorphone is an opioid analgesic used to manage pain across several clinical contexts.

• Moderate to severe acute pain: provides rapid analgesia after surgery or trauma.
• Cancer‑related pain: alleviates persistent severe pain associated with malignant disease.
• Post‑operative pain: controls pain during the immediate recovery period after operative procedures.

• Hydromorphone acts as a full agonist at the µ‑opioid receptors in the central nervous system. Binding to these receptors inhibits the release of nociceptive neurotransmitters, reduces neuronal excitability, and produces both analgesia and sedation. The drug’s high affinity for the µ‑receptor accounts for its potent pain‑relieving properties compared with weaker opioids.

Hydromorphone may cause a range of adverse reactions, from mild to life‑threatening.

Common Side Effects

• Nausea: feeling of sickness or urge to vomit.
• Constipation: reduced bowel movements and hard stools.
• Drowsiness: increased sleepiness or fatigue.
• Dry mouth: reduced salivation leading to a parched feeling.
• Sweating: excessive perspiration unrelated to temperature.

Serious or Rare Side Effects

• Respiratory depression: slowed or shallow breathing that can be fatal.
• Severe hypotension: dangerous drop in blood pressure.
• Addiction or dependence: compulsive use despite harmful consequences.
• Anaphylactic reaction: sudden severe allergic response.
• Adrenal insufficiency: inadequate production of adrenal hormones.

When prescribing or handling Hydromorphon Kalceks, several safety measures are essential.

• Respiratory assessment: evaluate baseline breathing function before initiation.
• Dependence monitoring: watch for signs of tolerance, misuse, or addiction.
• Dose adjustment: reduce dose in patients with renal or hepatic impairment.
• Concomitant CNS depressants: avoid or use with extreme caution alongside other sedatives.
• Elderly patients: start with the lowest effective dose and monitor closely.
• Store at room temperature: keep in the original container, protect from moisture and light.

Hydromorphone can interact with other medicines, altering its safety or effectiveness.

Major Interactions (Avoid)

• Other central nervous system depressants (e.g., benzodiazepines, barbiturates): may cause profound respiratory depression.
• Monoamine oxidase inhibitors (MAOIs): increase risk of serotonin syndrome and severe hypotension.
• Respiratory depressants (e.g., anesthetic gases): can exacerbate breathing suppression.

Moderate Interactions (Monitor Closely)

• CYP3A4 inhibitors (e.g., ketoconazole, erythromycin): may raise hydromorphone plasma levels.
• CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce analgesic effect.
• Anticholinergic agents: can worsen constipation and urinary retention.